$66.12
Value $10.0B
TGTX and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$66.12
Value $10.0B
$692.74
Value $257B
TG Therapeutics (TGTX) has a market value of $10.0B and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, TGTX moved +115.4% and TMO +22.6%. The P/E is 94.2 for TGTX and 36.4 for TMO. Dividend yield: TGTX none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TGTX$10.0B
TMO$257B
TMO is 26 times TGTX
Revenue, 12 months
TGTX$898M
TMO$47.4B
TMO is 53 times TGTX
Net income, 12 months
TGTX$106M
TMO$7.1B
TMO is 67 times TGTX
Operating margin
TGTX21.5%
TMO17.9%
3.6 points apart
ROIC
TGTX11.9%
TMO8.2%
3.7 points apart
P/E
TGTX94.2
TMO36.4
TGTX is 2.6 times TMO
Dividend yield
TGTX0.0%
TMO0.3%
0.3 points apart
5-year return
TGTX+143.3%
TMO+10.3%
133.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TGTX+143.3%
TMO+10.3%
| Period | TGTXWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +115.4%Price +115.4% | +22.6%Price +22.1% |
| 3 years since November 17, 2023 | +447.8%+76.3% a yearPrice +447.8% | +50.0%+14.5% a yearPrice +48.5% |
| 5 years since November 17, 2021 | +143.3%+19.5% a yearPrice +143.3% | +10.3%+2.0% a yearPrice +8.7% |
| 10 years since November 18, 2016 | +1,020.7%+27.3% a yearPrice +1,020.7% | +388.7%+17.2% a yearPrice +375.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TGTXTG TherapeuticsTMOThermo Fisher Scientific
| Price | $66.12 | $692.74 |
|---|---|---|
| Market value | $10.0B | $257B |
| Enterprise value (EV) | $10.2B | $293B |
| P/E | 94.2 | 36.4 |
| P/E, 5-year median | – | 32.7 |
| P/B | 17.5 | 4.7 |
| EV/EBIT | 52.8 | 34.6 |
| Free cash flow yield | 0.9% | 2.9% |
| Revenue, 12 months | $898M | $47.4B |
|---|---|---|
| Net income, 12 months | $106M | $7.1B |
| Free cash flow, 12 months | $86M | $7.6B |
| Earnings per share, 12 months | $0.67 | $18.96 |
| Revenue growth, year on year | 87.3% | 3.9% |
| Revenue growth a year, past | +426.7%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | 82.7% | – |
|---|---|---|
| Operating margin | 21.5% | 17.9% |
| Net margin | 11.8% | 14.9% |
| ROIC | 11.9% | 8.2% |
| ROE | 17.6% | 13.4% |
| Cash | $557M | $6.1B |
|---|---|---|
| Total debt | $754M | $41.4B |
| Net debt / EBITDA | 1.0 | 3.7 |
| Interest cover | 4.1× | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | 0.9% | 1.2% |
| Shareholder yield | 0.9% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 25.7 times TG Therapeutics ($10.0B), at today's prices.
Since November 18, 2016, TGTX's price moved +1,020.7% and TMO's +375.1%. With dividends: TGTX +1,020.7% (+27.3% a year), TMO +388.7% (+17.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for TG Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
At today's price, the P/E is 94.2 for TGTX and 36.4 for TMO. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 11.8% for TG Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin 21.5% and 17.9%. Revenue was $898M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.